Ultragenyx Pharmaceutical Inc. (RARE)
Company Info
| ISIN | US90400D1081 |
|---|---|
| CUSIP | 90400D108 |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | Jan 31, 2014 |
Highlights
| Market Cap | $4.70B |
|---|---|
| EPS (TTM) | -$7.21 |
| PEG Ratio | -0.24 |
| Total Revenue (TTM) | $383.25M |
| Gross Profit (TTM) | $314.68M |
| EBITDA (TTM) | -$367.24M |
| Year Range | $34.06 - $60.37 |
| Target Price | $91.62 |
| Short % | 3.94% |
| Short Ratio | 4.84 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: RARE vs. IOVA, RARE vs. SANA
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Ultragenyx Pharmaceutical Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Ultragenyx Pharmaceutical Inc. had a return of 6.78% year-to-date (YTD) and 31.50% in the last 12 months. Over the past 10 years, Ultragenyx Pharmaceutical Inc. had an annualized return of 1.34%, while the S&P 500 had an annualized return of 10.92%, indicating that Ultragenyx Pharmaceutical Inc. did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 6.78% | 19.77% |
| 1 month | -5.08% | -0.67% |
| 6 months | 18.72% | 10.27% |
| 1 year | 31.50% | 31.07% |
| 5 years (annualized) | 6.38% | 13.22% |
| 10 years (annualized) | 1.34% | 10.92% |
Monthly Returns
The table below presents the monthly returns of RARE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -7.76% | 17.25% | -9.73% | -8.89% | -5.64% | 2.39% | 9.54% | 26.12% | -2.17% | -8.21% | 6.78% | ||
| 2023 | -2.16% | -1.85% | -9.87% | 8.90% | 13.03% | -6.54% | -6.53% | -14.68% | -3.10% | -0.70% | 9.75% | 23.09% | 3.22% |
| 2022 | -16.84% | -3.73% | 7.87% | -2.66% | -33.65% | 27.21% | -10.69% | -10.49% | -13.17% | -2.29% | -10.28% | 27.63% | -44.90% |
| 2021 | 0.12% | 2.13% | -19.56% | -1.95% | -8.89% | -6.25% | -16.28% | 20.62% | -6.34% | -6.95% | -10.36% | 11.78% | -39.25% |
| 2020 | 23.04% | 6.72% | -20.77% | 36.01% | 13.29% | 14.26% | -0.08% | 8.83% | -3.37% | 22.28% | 17.95% | 16.78% | 224.12% |
| 2019 | 13.43% | 30.05% | 8.14% | -4.84% | -16.77% | 15.60% | -5.10% | -9.61% | -21.46% | -6.17% | -1.22% | 7.72% | -1.77% |
| 2018 | 15.03% | -10.38% | 6.65% | -0.29% | 43.98% | 5.01% | 2.91% | 7.10% | -9.90% | -36.53% | 10.77% | -18.99% | -6.25% |
| 2017 | 6.68% | 13.42% | -20.33% | -5.00% | -16.37% | 15.34% | 6.78% | -13.96% | -6.66% | -13.46% | 9.55% | -8.14% | -34.03% |
| 2016 | -49.95% | 8.62% | 3.80% | 6.81% | 8.10% | -33.09% | 29.38% | 4.17% | 7.62% | -16.85% | 32.72% | -10.19% | -37.32% |
| 2015 | 32.41% | -6.59% | 14.41% | -9.12% | 54.17% | 17.69% | 18.11% | -7.70% | -13.72% | 3.16% | -1.04% | 14.10% | 155.65% |
| 2014 | 31.98% | -12.32% | -20.68% | -3.15% | 19.52% | -2.65% | 22.11% | 6.07% | -16.94% | -7.28% | 0.67% | 3.86% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of RARE is 64, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Ultragenyx Pharmaceutical Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Ultragenyx Pharmaceutical Inc. was 82.11%, occurring on Oct 18, 2023. The portfolio has not yet recovered.
The current Ultragenyx Pharmaceutical Inc. drawdown is 71.22%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -82.11% | Dec 24, 2020 | 708 | Oct 18, 2023 | — | — | — |
| -74.79% | Jul 21, 2015 | 1172 | Mar 16, 2020 | 186 | Dec 8, 2020 | 1358 |
| -49.59% | Mar 13, 2014 | 48 | May 20, 2014 | 232 | Apr 22, 2015 | 280 |
| -18.98% | Apr 27, 2015 | 4 | Apr 30, 2015 | 8 | May 12, 2015 | 12 |
| -14.6% | Feb 3, 2014 | 3 | Feb 5, 2014 | 5 | Feb 12, 2014 | 8 |
Volatility
Volatility Chart
The current Ultragenyx Pharmaceutical Inc. volatility is 7.08%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Ultragenyx Pharmaceutical Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |